검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD-1 monoclonal antibody (Anti-PD-1 monoclonal antibody) Shanghai Celfuture Biotech Co., Lt…·PD-1 ORR 23.1%·t½ 13 h |
|---|---|
Overview Program | Anti-PD-1 monoclonal antibody |
Overview Company | Shanghai Celfuture Biotech Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Colorectal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint inhibitor-induced 3M syndrome: a case report |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Half-life | 13 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC.. Understanding resistance to anti-programmed cell death protein 1 (PD-1) therapy is critical for developing reversal strategies. Although ectonucleotidase CD39 (ENTPD1) (CD39) + cluster of differentiation 8 (CD8) + T cells have been associat… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 23.1% |
Clinical ORR | 23.1% |
Clinical Result source | ClinicalTrials.gov NCT03459222 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-PD-1 monoclonal antibody (Anti-PD-1 monoclonal antibody) Shanghai Celfuture Biotech Co., Lt…·PD-1 ORR 23.1%·t½ 13 h |
|---|---|
Overview Program | Anti-PD-1 monoclonal antibody |
Overview Company | Shanghai Celfuture Biotech Co., Ltd. |
Overview Modality | ANTIBODY |
Overview Target | PD-1 |
Overview Indication | Colorectal Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint inhibitor-induced 3M syndrome: a case report |
MoA Biomarker | PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells high |
PK/PD Half-life | 13 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Sequential involvement of hypoxia and anti-PD-1 treatment in shaping tumor-regional CD39 + CD8 + T cells highlights immunotherapy-resistant features in NSCLC.. Understanding resistance to anti-programmed cell death protein 1 (PD-1) therapy is critical for developing reversal strategies. Although ectonucleotidase CD39 (ENTPD1) (CD39) + cluster of differentiation 8 (CD8) + T cells have been associat… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 23.1% |
Clinical ORR | 23.1% |
Clinical Result source | ClinicalTrials.gov NCT03459222 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교